-+ 0.00%
-+ 0.00%
-+ 0.00%

PAVmed Q3 2026 Net Loss More Than Doubles to $13.04 Million

PUBT·11/13/2026 13:04:16
PAVmed Q3 2026 Net Loss More Than Doubles to $13.04 Million
  • PAVmed's preliminary third-quarter 2026 net loss attributable to common stockholders widened 86% year-over-year to $11.75 million.
  • Revenue rose to $41,000, while operating expenses climbed 40% year-over-year to $6.77 million.
  • Lucid Diagnostics began receiving Medicare payments for EsoGuard in October, securing nationwide reimbursement.
  • Veris Health achieved implantable monitor design freeze and initiated animal testing, targeting an early 2027 FDA submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611130800PR_NEWS_USPR_____NY97046) on November 13, 2026, and is solely responsible for the information contained therein.